Highlights of This Issue 6953

SPECIAL FEATURES

CCR Translations
6955 MAGE: The Spell Is Broken
Katayoun Rezvani
See article p. 7058

CCR Drug Updates
6958 Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
Evan J. Lipson and Charles G. Drake

Molecular Pathways
6963 Novel Insights into the Role of Interleukin-27 and Interleukin-23 in Human Malignant and Normal Plasma Cells
Nicola Giuliani and Irma Airoldi

Perspective
6971 DNA Cytometry Testing for Cervical Cancer Screening: Approaches and Reporting Standards for New Technologies
Graham A. Colditz and John Crowley

Reviews
6973 DNA Repair: From Genome Maintenance to Biomarker and Therapeutic Target
Shadia Jalal, Jennifer N. Earley, and John J. Turchi

6985 Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives
Jessica Godin-Ethier, Laila-Aïcha Hanafi, Ciriaco A. Piccirillo, and Réjean Lapointe

HUMAN CANCER BIOLOGY

Neutrophil Degranulation and Immunosuppression in Patients with GBM: Restoration of Cellular Immune Function by Targeting Arginase I
Trisha R. Sippel, Jason White, Kamalika Nag, Vadim Tsiviank, Marci Klaassen, B.K. Kleischmidt-DeMasters, and Allen Waziri

Novel Chromosomal Rearrangements and Break Points at the 16q22.1 in Salivary Adenoid Cystic Carcinoma: Association with MYB–NFIB Chimeric Fusion, MYB Expression, and Clinical Outcome

Mast Cells in Tumor Microenvironment Promotes the In Vivo Growth of Pancreatic Ductal Adenocarcinoma
David Z. Chang, Ying Ma, Baoan Ji, Huamin Wang, Defeng Deng, Yan Liu, James L. Abbruzzese, Yong-juan Liu, Craig D. Logsdon, and Patrick Hwu

Two Distinct Routes to Oral Cancer Differing in Genome Instability and Risk for Cervical Node Metastasis

Serum Galectin-2, -4, and -8 Are Greatly Increased in Colon and Breast Cancer Patients and Promote Cancer Cell Adhesion to Blood Vascular Endothelium
Hannah Barrow, Xiuli Guo, Hans H. Wandall, Johannes W. Pedersen, Bo Fu, Qicheng Zhao, Chen Chen, Jonathan M. Rhodes, and Lu-Gang Yu
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>Journal</th>
</tr>
</thead>
<tbody>
<tr>
<td>7047</td>
<td>Tumor-Derived Autophagosome Vaccine: Mechanism of Cross-Presentation and Therapeutic Efficacy</td>
<td>Yuhuan Li, Li-Xin Wang, Puiyi Pang, Zhihua Cui, Sandra Aung, Daniel Haley, Bernard A. Fox, Walter J. Urba, and Hong-Ming Ha</td>
<td>The Journal of Clinical and Translational Research</td>
</tr>
<tr>
<td>7058</td>
<td>Improving T-cell Therapy for Relapsed EBV-Negative Hodgkin Lymphoma by Targeting Upregulated MAGE-A4</td>
<td>Conrad R. Cruz, Ulrike Gerdemann, Ann M. Leen, Jessica A. Shafer, Stephanie Ku, Benjamin Tzou, Terzah M. Horton, Andrea Sheehan, Amanda Copeland, Anas Younes, Cliona M. Rooney, Helen E. Heslop, and Catherine M. Bollard</td>
<td>The Journal of Clinical and Translational Research</td>
</tr>
<tr>
<td>7093</td>
<td>Synergistic Activity of Fenretinide and the Bel-2 Family Protein Inhibitor ABT-737 against Human Neuroblastsoma</td>
<td>Hua Fang, Theresa M. Harned, Ondrej Kalous, Vanessa Maldonado, Yves A. DeClerck, and C. Patrick Reynolds</td>
<td>The Journal of Clinical and Translational Research</td>
</tr>
<tr>
<td>7105</td>
<td>Reduced miR-128 in Breast Tumor—Initiating Cells Induces Chemotherapeutic Resistance via Bmi-1 and ABCG2</td>
<td>Yinghua Zhu, Fengyan Yu, Yu Jiao, Juan Feng, Wei Tang, Herui Yao, Chang Gong, Jingming Chen, Fengxi Su, Yan Zhang, and Erwei Song</td>
<td>The Journal of Clinical and Translational Research</td>
</tr>
</tbody>
</table>
GLIPIR1 Tumor Suppressor Gene Expressed by Adenoviral Vector as Neoadjuvant Intraprostatic Injection for Localized Intermediate or High-Risk Prostate Cancer Preceding Radical Prostatectomy

Guru Sonpavde, Timothy C. Thompson, Rajul K. Jain, Gustavo E. Ayala, Shinji Kurosaka, Kohji Edamura, Ken-ichi Tabata, Chengzhen Ren, Alexei A. Goltsov, Martha P. Mims, Teresa G. Hayes, Michael M. Ittmann, Thomas M. Wheeler, Adrian Gee, Brian J. Miles, and Dov Kaulman

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

Cytokeratin-19 and Mammaglobin Gene Expression in Circulating Tumor Cells from Metastatic Breast Cancer Patients Enrolled in North Central Cancer Treatment Group Trials, N0234/336/436/437

Monica M. Reinholz, Kathleen A. Kitzmann, Kathleen Tenner, David Hillman, Amylou C. Dueck, Timothy J. Hobday, Donald W. Northfelt, Alvaro Moreno-Aspitia, Vivek Roy, Betsy LaPlant, Jake B. Allred, Philip J. Stella, Wilma L. Lingle, and Edith A. Perez

ABOUT THE COVER

Human melanoma xenografts of UACC903 cells with activated BRAF mutation (V600E) were either untreated or treated with vehicle (DMSO) or the compounds riluzole, sorafenib, or riluzole with sorafenib. Upon termination of the experiment, the remaining tumors were excised and stained with activated caspase-3. This image is vehicle control. For details, see the article by Lee and colleagues on page 7080 of this issue.